165 related articles for article (PubMed ID: 36253240)
1. Adjuvant chemotherapy for high-grade appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Baron E; Sardi A; King MC; Nikiforchin A; Lopez-Ramirez F; Nieroda C; Gushchin V; Ledakis P
Eur J Surg Oncol; 2023 Jan; 49(1):179-187. PubMed ID: 36253240
[TBL] [Abstract][Full Text] [Related]
2. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
[TBL] [Abstract][Full Text] [Related]
3. Systemic chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade mucinous carcinoma peritonei of appendiceal origin.
Munoz-Zuluaga CA; King MC; Ledakis P; Gushchin V; Sittig M; Nieroda C; Zambrano-Vera K; Sardi A
Eur J Surg Oncol; 2019 Sep; 45(9):1598-1606. PubMed ID: 31109821
[TBL] [Abstract][Full Text] [Related]
4. Systemic Chemotherapy for High-Grade Mucinous Appendiceal Cancer with Peritoneal Spread After Unsuccessful CRS/HIPEC.
Baron E; Sardi A; King MC; Nikiforchin A; Lopez-Ramirez F; Nieroda C; Gushchin V; Ledakis P
Ann Surg Oncol; 2022 Oct; 29(11):6581-6589. PubMed ID: 35641710
[TBL] [Abstract][Full Text] [Related]
5. Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Benefit.
Bhutiani N; Grotz TE; Concors SJ; White MG; Helmink BA; Raghav KP; Taggart MW; Beaty KA; Royal RE; Overman MJ; Matamoros A; Scally CP; Rafeeq S; Mansfield PF; Fournier KF
Ann Surg Oncol; 2024 Jan; 31(1):614-621. PubMed ID: 37872456
[TBL] [Abstract][Full Text] [Related]
6. Impact of adjuvant chemotherapy on outcomes in appendiceal cancer.
Kolla BC; Petersen A; Chengappa M; Gummadi T; Ganesan C; Gaertner WB; Blaes A
Cancer Med; 2020 May; 9(10):3400-3406. PubMed ID: 32189461
[TBL] [Abstract][Full Text] [Related]
7. Comparing Survival Outcomes and Impact of EPIC in Patients Undergoing CRS/HIPEC for Mucinous Appendiceal Neoplasm.
Mercado M; Shamavonian R; Cheng E; Ahmadi N; Morris DL
Anticancer Res; 2023 Feb; 43(2):817-822. PubMed ID: 36697077
[TBL] [Abstract][Full Text] [Related]
8. The 7th Edition of the AJCC Staging Classification Correlates with Biologic Behavior of Mucinous Appendiceal Tumor with Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Milovanov V; Sardi A; Studeman K; Nieroda C; Sittig M; Gushchin V
Ann Surg Oncol; 2016 Jun; 23(6):1928-33. PubMed ID: 26714951
[TBL] [Abstract][Full Text] [Related]
9. Do Lymph Node Metastases Matter in Appendiceal Cancer with Peritoneal Carcinomatosis? A US HIPEC Collaborative Study.
Turner KM; Morris MC; Delman AM; Hanseman D; Johnston FM; Greer J; Walle KV; Abbott DE; Raoof M; Grotz TE; Fournier K; Dineen S; Veerapong J; Maduekwe U; Kothari A; Staley CA; Maithel SK; Lambert LA; Kim AC; Cloyd JM; Wilson GC; Sussman JJ; Ahmad SA; Patel SH
J Gastrointest Surg; 2022 Dec; 26(12):2569-2578. PubMed ID: 36258061
[TBL] [Abstract][Full Text] [Related]
10. Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Zambrano-Vera K; Sardi A; Munoz-Zuluaga C; Studeman K; Nieroda C; Sittig M; King MC; Sipok A; Gushchin V
Ann Surg Oncol; 2020 Jan; 27(1):179-187. PubMed ID: 31646450
[TBL] [Abstract][Full Text] [Related]
11. Iterative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Adenocarcinoma of the Appendix.
Lopez-Ramirez F; Gushchin V; Sittig M; King MC; Baron E; Nikiforchin A; Nieroda C; Sardi A
Ann Surg Oncol; 2022 Jun; 29(6):3390-3401. PubMed ID: 35133518
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
13. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
[TBL] [Abstract][Full Text] [Related]
14. Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience.
Feferman Y; Solomon D; Bhagwandin S; Kim J; Aycart SN; Feingold D; Sarpel U; Labow DM
Ann Surg Oncol; 2019 Feb; 26(2):482-489. PubMed ID: 30539491
[TBL] [Abstract][Full Text] [Related]
15. Impact of neoadjuvant systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal adenocarcinoma.
Flood MP; Roberts G; Mitchell C; Ramsay R; Michael M; Heriot AG; Kong JC
Asia Pac J Clin Oncol; 2024 Feb; 20(1):32-40. PubMed ID: 36880398
[TBL] [Abstract][Full Text] [Related]
16. Should We Be Doing Cytoreductive Surgery with HIPEC for Signet Ring Cell Appendiceal Adenocarcinoma? A Study from the US HIPEC Collaborative.
Levinsky NC; Morris MC; Wima K; Sussman JJ; Ahmad SA; Cloyd JM; Kimbrough C; Fournier K; Lee A; Dineen S; Dessureault S; Veerapong J; Baumgartner JM; Clarke C; Zaidi MY; Staley CA; Maithel SK; Leiting J; Grotz T; Lambert L; Hendrix RJ; Ronnekleiv-Kelly S; Pokrzywa C; Raoof M; Eng OS; Johnston FM; Greer J; Patel SH
J Gastrointest Surg; 2020 Jan; 24(1):155-164. PubMed ID: 31428960
[TBL] [Abstract][Full Text] [Related]
17. Utility of hyperthermic intraperitoneal chemotherapy in cases of incomplete cytoreductive surgery.
Mangieri CW; Moaven O; Valenzuela CD; Erali RA; Votanopoulos KI; Shen P; Levine EA
J Surg Oncol; 2022 Mar; 125(4):703-711. PubMed ID: 34841542
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection.
Grotz TE; Overman MJ; Eng C; Raghav KP; Royal RE; Mansfield PF; Mann GN; Robinson KA; Beaty KA; Rafeeq S; Matamoros A; Taggart MW; Fournier KF
Ann Surg Oncol; 2017 Sep; 24(9):2646-2654. PubMed ID: 28695394
[TBL] [Abstract][Full Text] [Related]
19. Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA).
Milovanov V; Sardi A; Ledakis P; Aydin N; Nieroda C; Sittig M; Nunez M; Gushchin V
Eur J Surg Oncol; 2015 May; 41(5):707-12. PubMed ID: 25633641
[TBL] [Abstract][Full Text] [Related]
20. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.
Kusamura S; Barretta F; Yonemura Y; Sugarbaker PH; Moran BJ; Levine EA; Goere D; Baratti D; Nizri E; Morris DL; Glehen O; Sardi A; Barrios P; Quénet F; Villeneuve L; Gómez-Portilla A; de Hingh I; Ceelen W; Pelz JOW; Piso P; González-Moreno S; Van Der Speeten K; Deraco M;
JAMA Surg; 2021 Mar; 156(3):e206363. PubMed ID: 33502455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
